RE-186 labeled 16.88 IgM and 88BV59 IgG human antibody studies to assess potential for radioimmunotherapy
Journal Article
·
· Journal of Nuclear Medicine
OSTI ID:197976
- Virginia Mason Medical Center, Seattle, WA (United States)
Two studies with Re-186-MAG{sub 2}GABA labeled human antibodies were carried out to assess feasibility for radioimmunotherapy. Antibodies 16.88 and 88BV59 react with different epitopes of CTA 16.88, a tumor associated antigen of colorectal carcinoma. In a phase I dose escalation study, 14 patients received 60 mg/m{sup 2} 16.88 IgM MoAb. The dose of Re-186 ranged from 25 mCi/m{sup 2} to 210 mCi/m{sup 2} divided into 3 weekly infusions. In a pilot study with 88BV59, a human IgG3k MoAb, 20 mg antibody was labeled with 25 mCi/m{sup 2} Re-186 and administered to 4 patients with colon carcinoma. Tumor targeting was seen in 12 of 14 patients with 16.88 and all 4 patients with 88BV59. Retention of antibody at the tumor was longer with 88BV59. One patient developed a rash. No other acute or delayed toxicities were observed. Human anti-human antibody did not develop in any patient. The slower metabolism of the 88BV59 IgG suggests that this form of immunoconjugate merits further investigation for use in radioimmunotherapy.
- OSTI ID:
- 197976
- Report Number(s):
- CONF-940605--
- Journal Information:
- Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: Suppl.5 Vol. 35; ISSN 0161-5505; ISSN JNMEAQ
- Country of Publication:
- United States
- Language:
- English
Similar Records
Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma
Use of second antibody in radioimmunotherapy
Improved radioimmunotherapy of hematologic malignancies
Journal Article
·
Wed Feb 28 23:00:00 EST 1990
· Journal of Clinical Oncology; (USA)
·
OSTI ID:6969352
Use of second antibody in radioimmunotherapy
Journal Article
·
Wed Dec 31 23:00:00 EST 1986
· NCI Monogr.; (United States)
·
OSTI ID:6518729
Improved radioimmunotherapy of hematologic malignancies
Technical Report
·
Mon Mar 23 23:00:00 EST 1992
·
OSTI ID:5376292